semaglutide bodybuilding or tirzepatide I used Semaglutide to get

Although doctors may recommend B12 injection for this purpose when weakness is related to peripheral neuropathy, more research is needed on effectiveness, and Medicare doesnt consider this medically necessary

doi: 10.3389/fphar.2024.1384834 Received 10 February 2024 Accepted 04 April 2024 Published 01 May 2024 Volume 15 - 2024 Edited by Norsham Juliana, Universiti Sains Islam Malaysia, Malaysia Reviewed by Marjanu Hikmah Elias, Universiti Sains Islam Malaysia, Malaysia Khairun Nain Bin Nor Aripin, Islamic Science University of Malaysia, Malaysia Updates Copyright 2024 Hassan, Abdel-Halim, El-Shenbaby, Helmy, Hammad, Habotta, El Nashar, Alghamdi, Aldahhan, Al-Khater, Almohaywi and Farrag

But here is a silver lining

Indications and Usage Wegovy (semaglutide) injection is indicated in combination with a reduced calorie diet and increased physical activity: To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight To reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbidity Wegovy (semaglutide) tablets are indicated in combination with a reduced calorie diet and increased physical activity to: Reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight Reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight in the presence of at least one weight-related comorbidity Limitations of Use: Concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products or with any GLP-1 receptor agonist is not recommended Important Safety Information for Wegovy WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures

A follow-up study of women with gestational diabetes mellitus (GDM) revealed that patients who developed T2D after 6 years exhibited significantly elevated plasma BCAA levels, which were closely associated with insulin resistance indices (73)

& Rottner, K